<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649620</url>
  </required_header>
  <id_info>
    <org_study_id>BC_cholesterol</org_study_id>
    <nct_id>NCT03649620</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol</brief_title>
  <official_title>A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <brief_summary>
    <textblock>
      This study was conducted to investigate the effects of daily supplementation of unripe
      Bokbunja extract on improvement of blood cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Forty
      subjects were randomly divided into unripe Bokbunja extract 600 mg or placebo group. The
      investigators measured total cholesterol, lipid profile, arteriosclerosis index,
      anthropometric index, oxidized LDL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of total cholesterol were assessed before and after the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Lipid profile(total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol, free fatty acid, Apolipoprotein A1, Apolipoprotein B, Lipoprotein a, hs-CRP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of lipid profile(total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol, free fatty acid, Apolipoprotein A1, Apolipoprotein B, Lipoprotein a, hs-CRP) were assessed before and after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Arteriosclerosis index(total cholesterol/HDL-cholesterol, LDL-cholesterol/HDL-cholesterol, triglyceride/HDL-cholesterol, (total HDL-cholesterol-HDL-cholesterol)/HDL-cholesterol, Apolipoprotein B/Apolipoprotein A1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of arteriosclerosis index(total cholesterol/HDL-cholesterol, LDL-cholesterol/HDL-cholesterol, triglyceride/HDL-cholesterol, (total HDL-cholesterol-HDL-cholesterol)/HDL-cholesterol, Apolipoprotein B/Apolipoprotein A1) were assessed before and after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Anthropometric index(weight, body mass index, waist hip ratio, waist, hip, fat percentage, lean body mass)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of anthropometric index(weight, body mass index, waist hip ratio, waist, hip, fat percentage, lean body mass) were assessed before and after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Oxidized LDL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of oxidized LDL were assessed before and after the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Blood Cholesterol</condition>
  <arm_group>
    <arm_group_label>unripe Bokbunja Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet(1 tablet/d, 600 mg/d) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>unripe Bokbunja Extract</intervention_name>
    <description>tablet(1 tablet/d, 600 mg/d) for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>unripe Bokbunja Extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>unripe Bokbunja Extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 20 and 65 years,

          -  Total cholesterol 200-239 mg/dl

          -  subjects giving written informed consent

        Exclusion Criteria:

          -  Cardiovascular disease, e.g. arrhythmia, heart failure, myocardial infarction

          -  History of disease that could interfere with the test products or impede their
             absorption, such as gastrointestinal disease or gastrointestinal surgery

          -  Participation in any other clinical trials within past 2 months

          -  Laboratory test, medical or psychological conditions deemed by the investigators to
             interfere with successful participation in the study

          -  Pregnancy or breast feeding etc,.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jong Ho Lee</investigator_full_name>
    <investigator_title>Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>Bokbunja</keyword>
  <keyword>Clinical Trial</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

